Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shigella sonnei O-antigen lipopolysaccharide is a structurally distinct, strain-specific glycolipid forming the outermost part of *S. sonnei*’s outer membrane. Its O-antigen is a polymer of two unusual sugars, 2-acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) and 2-acetamido-2-deoxy-L-fucose (FucNAc4N), not commonly found in other bacteria[3][5][7]. The O-antigen, linked via the core oligosaccharide to lipid A, serves as an immunodominant and protective antigen, facilitating immune evasion and contributing to pathogenesis[1][3][5]. The O-antigen’s unique and highly immunogenic structure makes it an ideal target for vaccines and monoclonal antibodies, which can protect against *Shigella sonnei* infection by promoting bacterial clearance without substantial toxicity if the lipid A moiety is modified[2][7][8]. Its presence and length affect bacterial interaction with phagocytes and susceptibility to host immune responses[3][5].
Antibodies binding to O-antigen promote immune-mediated killing (complement activation, opsonization) Vaccine-induced antibodies block invasion of host cells and promote clearance
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shigella sonnei O-antigen lipopolysaccharide (S. sonnei O-antigen LPS).